Mironid reaches $43.7M to date in Series A extension to fund kidney disease treatment studies
Mironid has raised a total of £35 million ($43.7 million) since its inception with the help of a Series A extension raise, setting it up to get its lead kidney disease program through IND-enabling development.
The extension saw new Big Pharma backer Roche Venture Fund join Mironid’s existing investors, which include Epidarex Capital and Sofinnova Partners. The raise follows on from an original Series A round of £4.3 million that the Scottish company completed back in June 2016.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.